Gunderson Dettmer has advised Tarsus Pharmaceuticals. Latham & Watkins has advised Alkeus Pharmaceuticals. Tarsus Pharmaceuticals (Nasdaq: TARS) has entered into a definitive agreement to acquire Alkeus...
Tarsus Pharmaceuticals Signs Agreement to Acquire Alkeus Pharmaceuticals
Replicate Bioscience and Instituto Butantan Announce Collaboration for srRNA Rabies Vaccine in Latin America
Gunderson Dettmer has advised Replicate Bioscience. Replicate Bioscience, a clinical-stage biotechnology company specializing in self-replicating RNA (srRNA) therapeutics, has entered into a collaboration agreement with Instituto...
City Therapeutics Partners with Biogen
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented City Therapeutics in the transaction. City Therapeutics, a Cambridge-based biopharmaceutical company pioneering RNA interference (RNAi)-based medicine, announced its...
City Therapeutics’ Collaboration with Bausch Lomb
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented City Therapeutics in the transaction. City Therapeutics, a biopharmaceutical company, announced it has entered into a collaboration with...
City Therapeutics’ $135 Million Series A Financing Round
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented City Therapeutics in the transaction. City Therapeutics, a biopharmaceutical company, announced raising $135 million in Series A financing...
Vignette Bio’s License Agreement with EpimAb Biotherapeutics
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Vignette Bio in the transaction. Vignette Bio (“Vignette”) and EpimAb Biotherapeutics, Inc. (“EpimAB”) announced they have entered into...
Xaira Therapeutics’ $1 Billion Funding
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Xaira Therapeutics in the transaction. Xaira Therapeutics (Xaira), an AI biotechnology company, from formation and through $1 billion...
Pipeline Therapeutics’ Global License and Development Agreement with Janssen
Gunderson Dettmer represented Pipeline Therapeutics on the deal. Pipeline Therapeutics, a clinical-stage biopharmaceutical company, entered into a global license and development agreement with Janssen Pharmaceutica NV...
Replicate Biosciences’ Licensing Agreement with Precision NanoSystems
Gunderson Dettmer advised Replicate Bioscience on the deal. Replicate Bioscience, a San Diego-based biotechnology company, announced its licensing agreement to collaborate with Precision NanoSystems, a developer of...
Brightseed’s $68 Million Series B Financing
Gunderson Dettmer represented Brightseed on the deal. Brightseed, a San Francisco-based developer of plant nutrient technology, announced its $68 million Series B financing led by Temasek. Brightseed...
Xencor’s $100 Million Collaboration Agreement with Johnson & Johnson
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Xencor on the deal. Xencor, a clinical-stage biopharmaceutical company, announced its $100 million collaboration agreement with Johnson &...
Tarsus Pharmaceuticals’ Strategic Partnership with LianBio
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP advised Tarsus Pharmaceuticals, Inc. on the deal. Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company, and...